Autoimmune Encephalitis clinical trials at UCSF
1 research study open to eligible people
Autoimmune encephalitis is a condition where the body's immune system attacks the brain. UCSF is running a trial to test how safe and effective a drug called Satralizumab is for patients with specific types of this disease. This study will also look at how the body processes the drug.
Showing trials for
Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-N-methyl-D-aspartic acid receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis.
San Francisco, California and other locations
Last updated: